Cannabis and mood;Cannabis e humor

Revista Brasileira de Psiquiatria

Volumn 32, Issue 2, 2010, Pages 173-180

  Sanches, Rafael Faria ^a,b   De Azevedo Marques, João Mazzoncini ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Instituto Nacional de Ciência e Tecnologia   (Brazil)

Author keywords

Bipolar disorder; Cannabis; Cross sectional studies; Depression; Risk factors

Indexed keywords

CANNABIS; LITHIUM;

AGGRESSION; BIPOLAR DISORDER; CANNABIS ADDICTION; COMORBIDITY; DEPRESSION; HOSPITALIZATION; HUMAN; MAJOR DEPRESSION; MANIA; MOOD CHANGE; MOOD DISORDER; PATIENT COMPLIANCE; PSYCHOSOCIAL CARE; REVIEW; RISK FACTOR; SUICIDE; TREATMENT RESPONSE;

BIPOLAR DISORDER; CANNABIS; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MARIJUANA ABUSE; MARIJUANA SMOKING; MOOD DISORDERS;

EID: 77958506724     PISSN: 15164446     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1516-44462010000200014     Document Type: Review

References (89)

1. Ashton CH. Adverse effects of cannabis and cannabinoids. Br J Anaesthesia. 1999;83(4):637-49.
2. Ashton CH. Pharmacology and effects of cannabis: a brief review. Br J Psychiatry. 2001;178:101-6.
3. Johns A. Psychiatric effects of cannabis. Br J Psychiatry. 2001;178:116-22.
4. Karniol IG. Cannabis sativa e derivados. In: Seibel SD, Toscano Jr A, editors. Dependência de drogas. São Paulo: Atheneu; 2001. p.131-42.
5. Hall W. The mental health effects of cannabis use. In: Gelder MG, López-Ibor JJ, Andreasen NC, editors. New Oxford textbook of psychiatry. New York: Oxford University Press; 2000. p. 550-3.
6. Nunez LA, Gurpegui M. Cannabis-induced psicosis: a cross-sectional comparison with acute schizopphrenia. Acta Psychiatr Scand. 2002;105(3):173-8. (Pubitemid 34280689)
7. Budney AJ, Hughes JR, Moore BA, Vandrey RG. A review of the validity and significance of the cannabis withdrawal syndrome. Am J Psychiatry. 2004;161(11):1967-77.
8. Leweke FM, Koethe D. Cannabis and psychiatric disorders: it is not only addiction. Addict Biol. 2008;13(2):264-75. (Pubitemid 351692982)
9. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA. 1990;264(19):2511-8.
10. Kessler RC, Crum RM, Warner LA, Nelson CB, Schulenberg J, Anthony JC. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Arch Gen Psychiatry. 1997;54(4):313-21.
11. Farrell M, Howes S, Taylor C, Lewis G, Jenkins R, Bebbington P, Jarvis M, Brugha T, Gill B, Meltzer H. Substance misuse and psychiatric comorbidity: an overview of the OPCS National Psychiatric Morbidity Survey. Addict Behav. 1998;23(6):909-18. (Pubitemid 28443201)
12. Volkow ND. The reality of comorbidity: depression and drug abuse. Biol Psychiatry. 2004;56(10):714-7.
13. Strakowski SM, DelBello MP, Fleck DE, Arndt S. The impact of substance abuse on the course of bipolar disorder. Biol Psychiatry. 2000;48(6):477-85.
14. Kessler RC. The epidemiology of dual diagnosis. Biol Psychiatry. 2004;56(10):730-7.
15. Sonne SC, Brady KT, Morton WA. Substance abuse and bipolar affective disorder. J Nerv Ment Dis. 1994(6);182:349-52.
16. Feinman JA, Dunner DL. The effect of alcohol and substance abuse on the course of bipolar affective disorder. J Affective Disord. 1996;37(1):43-9.
17. Strakowski SM, DelBello MP, Fleck DE, Adler CM, Anthenelli RM, Keck PE Jr, Arnold, LM, Amicone J. Effects of co-occurring cannabis use disorders on the course of bipolar disorder after a first hospitalization for mania. Arch Gen Psychiatry. 2007;64(1):57-64. (Pubitemid 46041739)
18. Henquet C, Krabbendam L, de Graaf R, ten Have M, van Os J. Cannabis use and expression of mania in the general population. J Affect Disord. 2006;95(1-3):103-10.
19. Goldberg JF, Garno JL, Leon AC, Kocsis JH, Portera L. A history of substance abuse complicates remission from acute mania in bipolar disorder. J Clin Psychiatry. 1999;60(11):733-40.
20. van Rossum I, Boomsma M, Tenback D, Reed C, van Os J; EMBLEM Advisory Board. Does cannabis use affect treatment outcome in bipolar disorder? A longitudinal analysis. J Nerv Ment Dis. 2009;197(1):35-40.
21. DelBello MP, Hanseman D, Adler CM, Fleck DE, Strakowski SM. Twelve-month outcome of adolescents with bipolar disorder following first hospitalization for a manic or mixed episode. Am J Psychiatry. 2007;164(4):582-90. (Pubitemid 46650189)
22. Brown ES, Suppes T, Adinoff B, Thomas NR. Drug abuse and bipolar disorder: comorbidity or misdiagnosis? J Affect Disord. 2001;65:105-15. (Pubitemid 32448933)
23. Cassidy F, Ahearn EP, Carroll BJ. Substance abuse in bipolar disorder. Bipolar Disord. 2001;3(4):181-8.
24. Strakowski SM, Sax KW, McElroy SL, Keck PE Jr, Hawkins JM, West SA. Psychiatric and substance abuse syndrome co-occurrence in bipolar disorder following a first psychiatric hospitalization. J Clin Psychiatry. 1998;59(9):465-71.
25. Mueser KT, Drake RE, Wallach MA. Dual diagnosis: a review of etiological theories. Addict Behav. 1998;23(6):717-34.
26. DellBello MP, Strakowski SM, Sax KW, McElroy SL, Keck PE Jr, West SA, Kmetz GF. Familial rates of affective and substance use disorders in patients with first-episode mania. J Affect Disord. 1999;56(1):55-60.
27. Fu Q, Heath AC, Bucholz KK, Nelson E, Goldberg J, Lyons MJ, True WR, Jacob T, Tsuang MT, Eisen SA. Shared genetic risk of major depression, alcohol dependence and marijuana dependence: the contribution from antisocial personality disorder in men. Arch Gen Psychiatry. 2002;59(12):1125-32.
28. Asarnow JR. Children at risk for schizophrenia: converging lines of evidence. Schizophr Bull. 1988;14(4):613-31.
29. Moeller FG, Barratt ES, Dougherty DM, Schmitz JM, Swann AC. Psychiatric aspects of impulsivity. Am J Psychiatry. 2001;158(11):1783-93.
30. Swann AC, Dougherty DM, Pazzaglia PJ, Pham M, Moeller FG. Impulsivity: a link between bipolar disorder and substance abuse. Bipolar Disord. 2004;6(3):204-12. (Pubitemid 38702296)
31. Sasson Y, Chopra M, Harrari E, Amitai K, Zohar J. Bipolar comorbidity: from diagnostic dilemmas to therapeutic challenge. Int J Neuropsychopharmacol. 2003;6(2):139-44. (Pubitemid 36850966)
32. Ribeiro M, Laranjeira R, Cividanes G. Bipolar disorders and substance abuse. Rev Psiq Clin. 2005;32(Supl 1):78-88.
33. Merikangas KR, Herrell R, Swendsen J, Rössler W, Ajdacic-Gross V, Angst J. Specificity of bipolar spectrum conditions in the comorbidity of mood and substance use disorders: results from the Zurich cohort study. Arch Gen Psychiatry. 2008;65(1):47-52.
34. Levin FR, Hennessy G. Bipolar disorder and substance abuse. Biol Psychiatry. 2004;56(10):738-48.
35. Ashton CH, Moore PB, Gallagher P, Young AH. Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential. J Psychopharmacol. 2005;19(3):293-300. (Pubitemid 40694948)
36. Degenhardt L, Hall W, Lynskey M, Coffey C, Patton G. The association between cannabis use and depression: a review of the evidence. In: Castle D, Murray R, editors. Marijuana and madness. Cambridge: Cambridge University Press; 2004. p.54-74.
37. Mathew RJ, Wilson WH, Tant SR. Acute changes in cerebral blood flow associated with marijuana smoking. Acta Psychiatr Scand. 1989;79(2):118-28.
38. D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, Gueorguieva R, Cooper TB, Krystal JH. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry. 2005;57(6):594-608. (Pubitemid 40409699)
39. Murray RM, Sham P, Van Os J, Zanelli J, Cannon M, McDonald C. A developmental model for similarities and dissimilarities between schizophrenia and bipolar disorder. Schizophr Res. 2004;71(2-3):405-16. (Pubitemid 39330519)
40. Michael N, Erfurth A, Ohrmann P, Gossling M, Arolt V, Heindel W, Pfleiderer B. Acute mania is accompanied by elevated glutamate/glutamine levels within the left dorsolateral prefrontal cortex. Psychopharmacology (Berl). 2003;168(3):344-6. (Pubitemid 36920919)
41. Ketter TA, Wang PW The emerging differential roles of GABAergic and antiglutamatergic agents in bipolar disorders. J Clin Psychiatry. 2003;64(Suppl 3):15-20.
42. Friedman SD, Dager SR, Parow A, Hirashima F, Demopulos C, Stoll AL, Lyoo IK, Dunner DL, Renshaw PF. Lithium and valproic acid treatment effects on brain chemistry in bipolar disorder. Biol Psychiatry. 2004;56(5):340-8. (Pubitemid 39164519)
43. Tomasini MC, Ferraro L, Bebe BW, Tanganelli S, Cassano T, Cuomo V, Antonelli T. Delta(9)-tetrahydrocannabinol increases endogenous extracellular glutamate levels in primary cultures of rat cerebral cortex neurons: involvement of CB(1) receptors. J Neurosci Res. 2002;68(4):449-53.
44. Post RM, Rubinow DR, Ballenger JC. Conditioning, sensitization, and kindling: Implications for the course of affective illness. In: Post RM, Ballenger JC, editors. The neurobiology of mood disorders. Baltimore: Williams & Wilkins; 1984; p.432-66.
45. Goodwin FK, Jamison KR. Manic depressive illness. New York: Oxford University Press; 1990.
46. Lieberman JA, Kinon BJ, Loebel AD. Dopaminergic mechanisms in idiopathic and drug induced psychoses. Schizophr Bull. 1990;16(1):97-110.
47. Bovasso GB. Cannabis abuse as a risk factor for depressive symptoms. Am J Psychiatry. 2001;158(12):2033-7.
48. van Laar M, van Dorsselaer S, Monshouwer K, de Graaf R. Does cannabis use predict the first incidence of mood and anxiety disorders in the adult population? Addiction. 2007;102(8):1251-60.
49. Carroll KM. Behavioral therapies for co-occuring substance use and mood disorders. Biol Psychiatry. 2004;56(10):778-84.
50. Ridgley MS, Johson S. Drug and alcohol services. In: Thornicroft G, Szmukler G, editors. Textbook of community psychiatry. Devon: Oxford University Press; 2001. p.347-67.
51. Raimo EB, Schuckit MA. Alcohol dependence and mood disorders. Addict Behav. 1998;23(6):933-46.
52. Sanches RF, Assunção S, Hetem LA. Impacto da comorbidade no diagnóstico e tratamento do transtorno bipolar. Rev Psiq Clin. 2005;32(Suppl.1):71-7.
53. Weiss RD, Greenfield SF, Najavits LM, Soto JA, Wyner D, Tohen M, Griffin ML. Medication compliance among patients with bipolar disorder and substance use disorder. J Clin Psychiatry. 1998;59(4):172-4.
54. Potvin S, Stip E, Roy JY. The effect of quetiapine on cannabis use in 8 psychosis patients with drug dependency. Can J Psychiatry. 2004;49(10):711-20.
55. Grinspoon L, Bakalar JB. The use of cannabis as a mood stabilizer in bipolar disorder: anecdotal evidence and the need for clinical research. J Psychoactive Drugs. 1998;30(2):171-7.
56. Gruber AJ, Pope HG Jr, Brown ME. Do patients use marijuana as an antidepressant? Depression. 1996;4(2):77-80.
57. Regelson W, Butler JR, Schulz J, Kirk T, Peek L, Green ML, Zalis MO. Delta-9-THC as an effective antidepressant and appetitestimulating agent in advanced cancer patients. In Braude M C, Szara S, editors. The pharmacology of marihuana. New York: Raven Press; 1976. p.763-76.
58. Goodwin G, Sachs G. Definitions: Diagnosis and comorbidity. Bipolar disorder - fast facts. Oxford: Health Press; 2004.
59. Zuardi AW, Crippa JA, Hallak JE, Moreira FA, Guimarães FS. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res. 2006;39(4):421-9.
60. Porter R, Ferrier N, Ashton H. Anticonvulsants as mood stabilisers. Adv Psychiatr Treat. 1999;5:96-103.
61. Ashton H, Young AH. GABA-ergic drugs: exit stage left, enter stage right. J Psychopharmacol. 2003;17(2):174-8.
62. Valvassori SS, Elias G, de Souza B, Petronilho F, Dal-Pizzol F, Kapczinski F, Trzesniak C, Tumas V, Dursun S, Chagas MH, Hallak JE, Zuardi AW, Quevedo J, Crippa JA. Effects of cannabidiol on amphetamine-induced oxidative stress generation in an animal model of mania. J Psychopharmacol. In press 2009.
63. Zuardi A, Crippa J, Dursun S, Morais S, Vilela J, Sanches R, Hallak J. Cannabidiol was ineffective for manic episode of bipolar affective disorder. J Psychopharmacol. 2010;24(1):135-7.
64. Compton WM, Cottler LB, Jacobs JL, Ben-Abdallah A, Spitznagel El. The role of psychiatric disorders in predicting drug dependence outcomes. Am J Psychiatry. 2003;160(5):890-5.
65. Grant BF. Comorbidity between DSM-IV drug use disorders and major depression: results of a national survey of adults. J Subst Abuse. 1995;7(4):481-97.
66. Chen CY, Wagner FA, Anthony JC. Marijuana use and the risk of Major Depressive Episode. Epidemiological Evidence from the United States National Comorbidity Survey. Soc Psychiarty Psychiatr Epidemiol. 2002;37(5):199-206.
67. Degenhardt L, Hall W, Lynskey M. The relationship between cannabis use, depression and anxiety among Australian adults: findings from the National Survey of Mental Health and Well-Being. Soc Psychiarty Psychiatr Epidemiol. 2001;36(5):219-27.
68. Rey JM, Sawyer MG, Raphael B, Patton GC, Lynskey M. Mental health of teenagers who use cannabis: results of an Australian survey. Br J Psychiatry. 2002;180:216-21.
69. Fergusson DM, Horwood LJ, Swain-Campbell N. Cannabis use and psychosocial adjustment in adolescent and young adulthood. Addiction. 2002;97(9):1123-35
70. Angst J. Comorbidity of mood disorders: a longitudinal prospective study. Br J Psychiatry Suppl. 1996;30:31-7. (Pubitemid 26179804)
71. Rey JM, Tennant CC. Cannabis and mental health. BMJ. 2002;325(7374):1183- 4.
72. Macleod J, Oakes R, Copello A, Crome I, Egger M, Hickman M, Oppenkowski T, Stokes-Lampard H, Davey Smith G. Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies. Lancet. 2004;363(9421):1579-88. (Pubitemid 38625660)
73. Macleod J, Hickman M. Commentary: understanding pathways to cannabis use and from use to harm. Int J Epidemiol. 2006;35(3):680-2. (Pubitemid 43985560)
74. Kandel D, Chen K. Types of marijuana users by longitudinal course. J Studies Alcohol. 2000;61(3):367-78. (Pubitemid 30246948)
75. Hofstra M, van der Ende J, Verhultz F. Child and adolescent problems predict DSM-IV disorders in adulthood: a 14-year follow-up of a dutch epidemiological sample. J Am Acad Child Adolescent Psychiatry. 2002;41(2):182-9.
76. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370(9584):319-28.
77. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffi tt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ. 2002;325(7374):1212-3. (Pubitemid 35398785)
78. Brook DW, Brook JS, Zhang C, Cohen P, Whiteman M. Drug use and the risk of major depressive disorder, alcohol dependence and substance use disorders. Arch Gen Psychiatry. 2002;59(11):1039-44.
79. Patton GC, Coffey C, Carlin JB, Degenhardt L, Lynskey M, Hall W. Cannabis use and mental health in young people: cohort study. BMJ. 2002;325(7374):1195- 8. (Pubitemid 35398781)
80. Borowsky IW, Ireland M, Resnick MD. Adolescent suicide attempts: risks and protectors. Pediatrics. 2001;107(3):485-93. (Pubitemid 32183181)
81. Brook JS, Rosen Z, Brook DW. The effect of early marijuana use on later anxiety and depressive symptoms. New York: NYS Psychologist; 2001. p.35-40.
82. Wade TJ, Pevalin DJ. Adolescent delinquency and health. Can J Criminol Crim Just. 2005;47:619-54.
83. Beard JR, Dietrich UC, Brooks LO, Brooks RT, Heathcote K, Kelly B. Incidence and outcomes of mental disorders in a regional population: the Northern Rivers Mental Health Study. Aust N Z J Psychiatry. 2006;40(8):674-82. (Pubitemid 43984970)
84. Harder VS, Morral AR, Arkes J. Marijuana use and depression among adults: Testing for causal associations. Addiction. 2006;101(10):1463-72. (Pubitemid 44337771)
85. Harder VS, Stuart EA, Anthony JC. Adolescent cannabis problems and young adult depression: male-female stratified propensity score analyses. Am J Epidemiol. 2008;168(6):592-601.
86. Marihuana Treatment Project Research Group. Brief treatments for cannabis dependence: findings from a mutisite trial. J Consult Clin Psychol. 2004;72(3):455-66.
87. Riggs PD, Mikulich-Gilbertson SK, Davies RD, Lohman M, Klein C, Stover SK. A randomized controlled trial of fluoxetine and cognitive behavioral therapy in adolescents with major depression, behavior problems, and substance use disorders. Arch Pediatr Adolesc Med. 2007;161(11):1026-34.
88. Bhattacharyya S, Crippa JA, Martin-Santos R, Winton-Brown T, Fusar-Poli P. Imaging the neural effects of cannabinoids: current status and future opportunities for psychopharmacology. Curr Pharm Des. 2009;15(22):2603-14.
89. Crippa JA, Zuardi AW, Martín-Santos R, Bhattacharyya S, Atakan Z, McGuire P, Fusar-Poli P. Cannabis and anxiety: a critical review of the evidence. Hum Psychopharmacol. 2009;24(7):515-23.